Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Efficacy and Pharmacokinetics of N9-GP (nonacog beta pegol) in Haemophilia B
2011-000826-31Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Incidence of inhibitory antibodies against factor IX (FIX). Started Jun 2012; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-000826-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000826-31.